Published in
American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 11(65), 2021
DOI: 10.1128/aac.00364-21
Links
Tools
Rifampicin-Monoresistant Tuberculosis Is Not the Same as Multidrug-Resistant Tuberculosis: a Descriptive Study from Khayelitsha, South Africa
Journal article published in 2021 by
Zubeida Salaam-Dreyer,
Elizabeth M. Streicher 
,
Frederick A. Sirgel,
Fabrizio Menardo,
Sonia Borrell,
Miriam Reinhard,
Anna Doetsch,
Patrick G. T. Cudahy,
Erika Mohr-Holland,
Johnny Daniels,
Anzaan Dippenaar ,
Mark P. Nicol,
Sebastien Gagneux ,
Robin M. Warren,
Helen Cox
,
Frederick A. Sirgel,
Fabrizio Menardo,
Sonia Borrell,
Miriam Reinhard,
Anna Doetsch,
Patrick G. T. Cudahy,
Erika Mohr-Holland,
Johnny Daniels,
Anzaan Dippenaar ,
Mark P. Nicol,
Sebastien Gagneux ,
Robin M. Warren,
Helen Cox
This paper is made freely available by the publisher.
Full text: Download
Data provided by 
Abstract
Rifampin monoresistance (RMR; rifampin resistance and isoniazid susceptibility) accounts for 38% of all rifampin-resistant tuberculosis (RR-TB) in South Africa and is increasing. We aimed to compare RMR-TB with multidrug-resistant TB (MDR-TB) in a setting with high TB, RR-TB, and HIV burdens.